Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Werewolf Therapeutics (HOWL) Assets Average (2021 - 2025)

Werewolf Therapeutics (HOWL) has disclosed Assets Average for 5 consecutive years, with $86.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Assets Average fell 41.38% to $86.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $86.1 million, a 41.38% decrease, with the full-year FY2024 number at $150.9 million, down 9.94% from a year prior.
  • Assets Average was $86.1 million for Q3 2025 at Werewolf Therapeutics, down from $99.9 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $190.2 million in Q2 2023 to a low of $86.1 million in Q3 2025.
  • A 5-year average of $157.5 million and a median of $171.0 million in 2022 define the central range for Assets Average.
  • Peak YoY movement for Assets Average: grew 21.48% in 2022, then crashed 41.38% in 2025.
  • Werewolf Therapeutics' Assets Average stood at $178.8 million in 2021, then fell by 6.98% to $166.3 million in 2022, then rose by 5.58% to $175.6 million in 2023, then decreased by 23.99% to $133.5 million in 2024, then plummeted by 35.5% to $86.1 million in 2025.
  • Per Business Quant, the three most recent readings for HOWL's Assets Average are $86.1 million (Q3 2025), $99.9 million (Q2 2025), and $117.1 million (Q1 2025).